The narrowing of Mylan's antitrust claims reduces the expected value of the litigation for VTRS. The case continues but with weaker prospects; monitor for summary judgment motions or settlement developments. TEVA benefits from the dismissal of several theories.
Price Chart
Executive Summary
The district court partially granted Teva's motion to dismiss Mylan's antitrust complaint, dismissing with prejudice allegations regarding sham citizen petitions, ANDA lawsuits, market shift, copay assistance, and foreign conduct, but allowing claims based on the DAW campaign, exclusionary PBM agreements, and the 2020 reclassification petition to proceed. The ruling significantly narrows Viatris's (Mylan's) antitrust case against Teva, reducing the potential scope of damages.
Court Ruling Details
Key Facts
- Court adopted Special Master's R&R, partially granting Teva's motion to dismiss.
- Antitrust allegations regarding 20mg citizen petitions, 20mg ANDA litigation, market shift, copay assistance, and foreign conduct dismissed with prejudice.
- Allegations about DAW campaign, exclusionary PBM agreements, and 2020 reclassification petition/lawsuit survive.
- Lanham Act claim (Count II) and state law claims (Counts III-VI) survive.
- No damages awarded; case proceeds on a narrower set of theories.
- Opinion dated April 13, 2026.
Financial Impact
Mylan's antitrust case against Teva survives but with reduced scope; potential treble damages now limited to surviving claims (DAW campaign, PBM agreements, 2020 reclassification). No dollar amount stated in ruling.
Risk Factors
- Case may be further narrowed on summary judgment or at trial.
- Mylan may settle on less favorable terms given reduced claims.
- Appeal of dismissed claims is unlikely given interlocutory nature of ruling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-15mpe8hi-VTRS |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $16.29 $16.94 | ▲ +3.99% | ▲ +3.39% | $17.60 (+8.04%) |
Jun 25, 2026 14w ago | 144 | $16.33 $17.28 | ▲ +5.82% | ▲ +4.56% | $17.60 (+7.78%) |
Jun 18, 2026 15w ago | 8-K | $15.38 $17.29 | ▲ +12.42% | ▲ +12.57% | $17.60 (+14.43%) |
Jun 15, 2026 15w ago | 8-K | $16.04 $16.31 | ▲ +1.68% | ▲ +1.48% | $17.60 (+9.73%) |
May 13, 2026 20w ago | Court Ruling | $17.37 $16.31 | ▼ −6.10% | ▼ −5.49% | $17.60 (+1.32%) |
May 7, 2026 21w ago | 8-K | $17.39 $15.56 | ▼ −10.52% | ▼ −13.66% | $17.60 (+1.21%) |
May 4, 2026 21w ago | 8-K | $15.52 $15.69 | ▲ +1.10% | ▼ −3.86% | $17.60 (+13.40%) |
May 4, 2026 21w ago | Court Ruling | $15.20 $15.69 | ▲ +3.22% | ▼ −2.56% | $17.60 (+15.79%) |
May 4, 2026 21w ago | Court Ruling | $15.20 $15.69 | ▲ +3.22% | ▼ −2.56% | $17.60 (+15.79%) |
Apr 13, 2026 24w ago | Court Ruling | $13.83 $16.92 | ▲ +22.34% | ▲ +14.59% | $17.60 (+27.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access